Enjuvia (synthetic conjugated estrogens, B) tablets, 0.625 mg, 30-count tablets per bottle, Rx only, Mfg. By: Teva Pharmaceuticals USA, Sellersville PA 18960; Repacked & distributed by: Physicians Total Care, Inc., Tulsa, OK 74146; NDC 54868-6163-1.

Subpotent (Single ingredient) drug : This is a sub recall of Teva's Enjuvia due to low Out of Specification (OOS) assay results.

Recall #: D-091-2013
Affected scope: 9 bottles
Initiated: April 8, 2011

Compiled from official public sources by the publisher. · Updated September 2026

Verify with FDA Drug →

View my saved recalls

Physicians Total Care, Inc. recalled Enjuvia (synthetic conjugated estrogens, B) tablets, 0.625 mg, 30-count tablets per bottl… - a low-severity action.

Enjuvia (synthetic conjugated estrogens, B) tablets, 0.625 mg, 30-count tablets per bottl… was recalled by Physicians Total Care, Inc. in December 19, 2012. Reason: Subpotent (Single ingredient) drug : This is a sub recall of Teva's Enjuvia due to low Out of Specification (…. Check the official notice for the remedy. Verify recall #D-091-2013 with the FDA Drug before acting.

The recall

Physicians Total Care, Inc. issued this low-severity FDA Drug recall-Subpotent (Single ingredient) drug : This is a sub recall of Teva's Enjuvia due to low Out of Specification (….

Low
severity level: Class III
classification: December 19, 2012
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-091-2013 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified low severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Enjuvia (synthetic conjugated estrogens, B) tablets, 0.625 mg, 30-count tablets per bottle, Rx only, Mfg. By: Teva Pharmaceuticals USA, Sellersville PA 18960; Repacked & distributed by: Physicians Total Care, Inc., Tulsa, OK 74146; NDC 54868-6163-1.

Reason for recall

Subpotent (Single ingredient) drug : This is a sub recall of Teva's Enjuvia due to low Out of Specification (OOS) assay results.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Low (Class III)
Status	Terminated
Recall number	D-091-2013
Date reported	December 19, 2012
Date initiated	April 8, 2011
Recalling firm	Physicians Total Care, Inc.
Firm location	Tulsa, OK
Affected scope	9 bottles
Distribution	VA

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-091-2013) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

Subpotent (Single ingredient) drug : This is a sub recall of Teva's Enjuvia due to low Out of Specification (OOS) assay results.

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on December 19, 2012. Severity: Low. Recall number: D-091-2013.

Where was the recalled product distributed? ▼

Distribution: VA.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Low), closest by report date among other firms and states.

Pure Apricot Pecan Flats, 10 units/case, … 2012-12-19 Ella's Kitchen yum yummy milk + vanilla b… 2012-12-19 Ella's Kitchen yum yummy apple + ginger b… 2012-12-19 Caziant (desogestrel and ethinyl estradio… 2012-12-26

Similar Drugs & Medications · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Nalbuphine HCl Injection, 20 mg/mL, 10 mL… 2012-12-26 Clean & Clear advantage, 3-in-1 foaming w… 2012-12-26 Lidocaine HCl Injection, USP, 1% (10 mg/m… 2012-12-26 Novarel¿ (Chorionic Gonadotropin for inje… 2012-12-12

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported December 19, 2012. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026